Comparison of the distribution of properdin factor B (Bf) genotypes between type I and type II diabetes in Japanese

1984 ◽  
Vol 20 (6) ◽  
pp. 1491
Author(s):  
K. Nanjo ◽  
M. Miyano ◽  
K. Okai ◽  
K. Kashiio ◽  
R. Miyashitao ◽  
...  
Keyword(s):  
Type Ii Diabetes ◽  
Type I ◽  
Type Ii ◽  
Factor B ◽  
Properdin Factor B

scholarly journals P006: Characterizing patients with newly-diagnosed diabetes mellitus in the emergency department: A one-year health records review

CJEM ◽  
2017 ◽  
Vol 19 (S1) ◽  
pp. S79
Author(s):  
H. Ali Khan ◽  
K. Gushulak ◽  
M. Columbus ◽  
I.G. Stiell ◽  
J.W. Yan
Keyword(s):  
Diabetic Ketoacidosis ◽  
Type Ii Diabetes ◽  
Type I ◽  
Type Ii ◽  
Newly Diagnosed ◽  
Health Records ◽  
The Mean ◽  
One Year ◽  
Diagnosed Diabetes ◽  
Newly Diagnosed Diabetes

Introduction: Diabetes mellitus is an increasingly prevalent chronic condition that is usually managed in an outpatient setting. However, the emergency department (ED) plays a crucial role in the management of diabetic patients, particularly for those who are presenting with newly diagnosed diabetes. Little research has been done to characterize the population of patients presenting to the ED with hyperglycemia with no previous diagnosis of diabetes. The objective of this study was to describe the epidemiology, treatment, and outcomes of patients who were newly diagnosed with diabetes in the ED and to compare those with newly diagnosed type I versus type II diabetes. Methods: A one-year health records review of newly diagnosed diabetes patients ≥18 years presenting to one of four tertiary care EDs was conducted. All patients with a discharge diagnosis of hyperglycemia, diabetic ketoacidosis or hyperosmolar hyperglycemic syndrome were screened, but only those who did not have a previous history of diabetes were included. Trained research personnel collected data on patient characteristics, management, disposition, and outcome. Descriptive statistics were used to summarize the data where appropriate. Results: Of 645 patients presenting with hyperglycemia in the study period, 112 (17.4%) were newly diagnosed diabetes patients. Of these patients, 30 (26.8%) were later diagnosed with type I diabetes and 82 (73.2%) were diagnosed with type II diabetes. For the newly diagnosed type I patients the mean (SD) age was 27.6 (9.9) and the mean (SD) age for type II patients was 52.4 (14.1). Of all the new onset patients, 26.8% were diagnosed with diabetic ketoacidosis. The percentage of patients diagnosed with diabetic ketoacidosis was higher in type I than type II (63.3% vs 13.4%; P<0.01). A total of 49 (43.8%) patients were admitted to the hospital, and more patients with type I were admitted compared to those with type II (66.7% vs 35.4 %; P<0.01). Conclusion: Limited research has been done to describe patients newly diagnosed with diabetes in the ED. Patients with type I were found to be more likely to present to the ED with serious symptoms requiring admission to hospital. Our findings demonstrate that the ED may have a strong potential role for improving diabetic care, by providing future opportunities for education and follow-up in the ED to reduce complications, particularly in type I.

CEMTIRESTAT ATTENUATED NEUROLOGICAL DISORDERS IN RAT MODELS OF TYPE I AND TYPE II DIABETES: A BEHAVIORAL STUDY

2018 ◽  
Vol 25 (3) ◽  
pp. 217-218
Author(s):  
Marta Šoltésová Prnová ◽  
Karol Švík ◽  
Štefan Bezek ◽  
Lucia Kovaciková ◽  
Cimen Karasu ◽  
...  
Keyword(s):  
Neurological Disorders ◽  
Type Ii Diabetes ◽  
Type I ◽  
Behavioral Study ◽  
Type Ii ◽  
Rat Models

scholarly journals Efficacy of lanthionine-stabilized angiotensin-(1-7) in type I and type II diabetes mouse models

Peptides ◽  
2019 ◽  
Vol 112 ◽  
pp. 78-84 ◽  
Author(s):  
Anneke Kuipers ◽  
Gert N. Moll ◽  
Elizabeth Wagner ◽  
Rick Franklin
Keyword(s):  
Mouse Models ◽  
Type Ii Diabetes ◽  
Type I ◽  
Type Ii ◽  
Diabetes Mouse

scholarly journals Therapeutic Strategies for Diabetes: Immune Modulation in Pancreatic β Cells

2021 ◽  
Vol 12 ◽  
Author(s):  
Sugyeong Jo ◽  
Sungsoon Fang
Keyword(s):  
Clinical Trials ◽  
T Cells ◽  
Type Ii Diabetes ◽  
Immune Modulation ◽  
Therapeutic Strategies ◽  
Immune Homeostasis ◽  
Type I ◽  
Type Ii ◽  
Pancreatic Β Cell ◽  
Β Cell

Increased incidence of type I and type II diabetes has been prevailed worldwide. Though the pathogenesis of molecular mechanisms remains still unclear, there are solid evidence that disturbed immune homeostasis leads to pancreatic β cell failure. Currently, autoimmunity and uncontrolled inflammatory signaling pathways have been considered the major factors in the pathogenesis of diabetes. Many components of immune system have been reported to implicate pancreatic β cell failure, including helper T cells, cytotoxic T cells, regulatory T cells and gut microbiota. Immune modulation of those components using small molecules and antibodies, and fecal microbiota transplantation are undergoing in many clinical trials for the treatment of type I and type II diabetes. In this review we will discuss the basis of molecular pathogenesis focusing on the disturbed immune homeostasis in type I and type II diabetes, leading to pancreatic β cell destruction. Finally, we will introduce current therapeutic strategies and clinical trials by modulation of immune system for the treatment of type I and type II diabetes patients.

scholarly journals Low serum C4 concentrations and peripheral neuropathy in type I and type II diabetes.

BMJ ◽  
1986 ◽  
Vol 292 (6536) ◽  
pp. 1671-1671 ◽  
Author(s):  
B G Jacob ◽  
W O Richter ◽  
P Schwandt ◽  
A Fateh-Moghadam ◽  
T N Witt
Keyword(s):  
Peripheral Neuropathy ◽  
Type Ii Diabetes ◽  
Type I ◽  
Type Ii ◽  
Low Serum

Knowledge of Hypoglycemic Symptoms and their Self-Management among patients with Type II Diabetes Mellitus

2021 ◽  
Vol 15 (11) ◽  
pp. 2961-2962
Author(s):  
Aneel Kumar ◽  
Zahid Ali Shaikh ◽  
Sham Lal Prithiani ◽  
Bashir Ahmed Shaikh ◽  
Imdad Ali Ansari ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type Ii Diabetes ◽  
Type Ii Diabetes Mellitus ◽  
Self Management ◽  
Type I ◽  
Type Ii ◽  
College Hospital ◽  
Cross Sectional ◽  
Medical College ◽  
Adequate Knowledge

Aim: To determine knowledge of hypoglycaemic symptoms & their self-management among pts with type II diabetes mellitus. Study Design: Descriptive, cross-sectional. Place and duration of study: OPD Clinic of Department of Medicine, Chandka Medical College Hospital Larkana from 23rd May 2019 to 22nd November 2019. Methodology: One hundred and thirty five patients with type II diabetes mellitus of age 35- 60 years were selected. Patients with type I DM and neuro-psychiatric illness were excluded. The symptoms of hypoglycemia and their responses to those symptoms were recorded. Results: The mean age of 47.07±6.04years and majority of the patients 83 (61.48%) were between 46-60 years of age. Seventy two (53.33%) were male and 63 (46.67%) were females. Mean duration of diabetes mellitus was 6.90±3.86 years. Adequate knowledge of hypoglycemic symptoms and their self-management among patients with type II diabetes mellitus was found in 62 (56.9%) patients. Conclusion: Hypoglycemic patients are significantly unaware of their condition and have a very low knowledge about hypoglycemia and its self-management. Keywords: Type II diabetes, Hypoglycemic symptoms, Knowledge

scholarly journals Cancer Biology and Prevention in Diabetes

Cells ◽  
2020 ◽  
Vol 9 (6) ◽  
pp. 1380 ◽  
Author(s):  
Swayam Prakash Srivastava ◽  
Julie E. Goodwin
Keyword(s):  
Type Ii Diabetes ◽  
Cancer Biology ◽  
Cancer Metastasis ◽  
Type I Diabetes ◽  
Type I ◽  
Type Ii ◽  
Mesenchymal Transition ◽  
Wide Range ◽  
Risk Of Cancer

The available evidence suggests a complex relationship between diabetes and cancer. Epidemiological data suggest a positive correlation, however, in certain types of cancer, a more complex picture emerges, such as in some site-specific cancers being specific to type I diabetes but not to type II diabetes. Reports share common and differential mechanisms which affect the relationship between diabetes and cancer. We discuss the use of antidiabetic drugs in a wide range of cancer therapy and cancer therapeutics in the development of hyperglycemia, especially antineoplastic drugs which often induce hyperglycemia by targeting insulin/IGF-1 signaling. Similarly, dipeptidyl peptidase 4 (DPP-4), a well-known target in type II diabetes mellitus, has differential effects on cancer types. Past studies suggest a protective role of DPP-4 inhibitors, but recent studies show that DPP-4 inhibition induces cancer metastasis. Moreover, molecular pathological mechanisms of cancer in diabetes are currently largely unclear. The cancer-causing mechanisms in diabetes have been shown to be complex, including excessive ROS-formation, destruction of essential biomolecules, chronic inflammation, and impaired healing phenomena, collectively leading to carcinogenesis in diabetic conditions. Diabetes-associated epithelial-to-mesenchymal transition (EMT) and endothelial-to-mesenchymal transition (EndMT) contribute to cancer-associated fibroblast (CAF) formation in tumors, allowing the epithelium and endothelium to enable tumor cell extravasation. In this review, we discuss the risk of cancer associated with anti-diabetic therapies, including DPP-4 inhibitors and SGLT2 inhibitors, and the role of catechol-o-methyltransferase (COMT), AMPK, and cell-specific glucocorticoid receptors in cancer biology. We explore possible mechanistic links between diabetes and cancer biology and discuss new therapeutic approaches.

Sign in / Sign up

Export Citation Format

Share Document